- Home
- PENG vs JANX Comparison
PENG vs JANX Comparison
Compare PENG & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENG | JANX |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 2900 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 959.2M | 790.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | PENG | JANX |
|---|---|---|
| Price | $27.71 | $16.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 12 |
| Target Price | $27.88 | ★ $48.73 |
| AVG Volume (30 Days) | ★ 1.3M | 999.3K |
| Earning Date | 04-01-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,000,000.00 |
| Revenue This Year | $13.75 | N/A |
| Revenue Next Year | $16.51 | N/A |
| P/E Ratio | $87.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.04 | $12.12 |
| 52 Week High | $29.80 | $35.34 |
Technical Indicators
Market Signals| Indicator | PENG | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 81.22 | 69.21 |
| Support Level | $22.13 | $12.93 |
| Resistance Level | $28.18 | $25.07 |
| Average True Range (ATR) | 1.30 | 0.66 |
| MACD | 0.79 | 0.14 |
| Stochastic Oscillator | 99.96 | 80.37 |
Price Performance
Historical ComparisonAbout PENG Penguin Solutions Inc. Ordinary Shares
Penguin Solutions Inc is an end-to-end technology company engaged in Intelligent Platform Solutions, Integrated Memory, and Optimized LED business. Its product include Servers, software, OCP HPC & AI system, Racks and Edge. Servers include AMD-based Serves, Intel-based Servers, etc. Software products include Scyld ClusterWare, Scyld Cloud Central, etc. OCP HPC & AI Systems includes OCP Servers & Storage and etc.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.